Long-term outcome of infliximab therapy in pediatric Crohn disease;Usage prolongé de l'infliximab dans la maladie de Crohn chez l'enfant

Archives de Pediatrie

Volumn 18, Issue 8, 2011, Pages 863-869

  Wanty, C ^a   Stephenne, X ^a   Sokal, E ^a   Smets, F ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ARTICLE; BIOLOGICAL THERAPY; CHILD; CHILD GROWTH; CLINICAL EVALUATION; CROHN DISEASE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; GROWTH RATE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CROHN DISEASE; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960596182     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2011.05.022     Document Type: Article

References (30)

1. Hyams J., Crandall W., Kugathasan S., et al. Induction and maintenance of infliximab therapy for the treatment of moderate-to-sever Crohn disease in children. Gastroenterology 2007, 132:863-873.
2. Stephens M.C., Shepanski M.A., Mamula P., et al. Safety and steroid sparing experience using infliximab for Crohn disease a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003, 98:104-111.
3. Lamireau T., Cezard J.P., Dabadie A., et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn disease. Inflamm Bowel Dis 2004, 6:745-750.
4. Crandall W., Hyams J., Kugathasan, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 2009, 49:183-190.
5. Wynands J., Belbouab R., Candon S., et al. 12-month follow-up after successful infliximab therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2008, 46:293-298.
6. Ruemmele F.M., Lachaux A., Cézard J.P., et al. Efficacy of infliximab in pediatric Crohn disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 2009, 15:388-394.
7. Friesen C.A., Calabro C., Christenson K., et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004, 39:265-269.
8. Mackey A.C., Green L., Liang L.C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:265-267.
9. Hyams J.S., Ferry G.D., Mandel F.S., et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991, 12:439-447.
10. Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010. [Epub ahead of print].
11. Hyams J.S., Lerer T., Griffiths A. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009, 15:816-822.
12. de Ridder L., Rings E.H., Damen G.M., et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008, 14:353-358.
13. Wewer V., Riis L., Vind I., et al. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr 2006, 42:40-45.
14. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the Accent I randomised trial. Accent I study group. Lancet 2002, 359:1541-1549.
15. Shamir R., Phillip M., Levine A. Growth retardation in pediatric Crohn's disease: pathogenesis and interventions. Inflamm Bowel Dis 2007, 13:620-628.
16. Levine A., Shamir R., Wine E., et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease. Am J Gastroenterol 2005, 100:1598-1604.
17. Sagiv-Friedgut K., Karban A., Weiss B., et al. Early-onset Crohn disease is associated with male sex and a polymorphism in the IL-6 promoter. J Pediatr Gastroenterol Nutr 2010, 50:22-26.
18. Veereman-Wauters G., Hyams J., Olson A., et al. Height of growth-delayed children with active Crohn's disease improve during treatment with infliximab. J Pediatr Gastroenterol Nutr 2006, 42:2-19.
19. Walters T.D., Gilman A.R., Griffiths A.M. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007, 13:424-430.
20. Pfefferkorn M., Burke G., Griffiths A., et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 2009, 48:168-174.
21. Sawczenko A., Ballinger A.B., Savage M.O., et al. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 2006, 118:124-129.
22. Cucchiara S., Escher J.C., Hildebrand H., et al. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies?. J Pediatr Gastroenterol Nutr 2009, 48:257-267.
23. Markowitz J. Early inflammatory bowel disease: different treatment response to specific or all medications?. Dig Dis 2009, 27:358-365.
24. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
25. Markowitz J., Grancher K., Kohn N., et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119:895-902.
26. Kugathasan S., Werlin S.L., Martinez A., et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000, 95:3189-3194.
27. Kim M.J., Lee J.S., Lee J.H., et al. Infliximab therapy in children with Crohn's disease: a one-year evaluation of efficacy comparing " top down" and " step up" strategies. Acta Paediatr 2011, 100:451-455.
28. Colletti R.B., Baldassano R.N., Milov D.E., et al. Variation in care in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2009, 49:297-303.
29. Rosh J.R., Lerer T., Markowitz J., et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009, 104:3042-3049.
30. Bosani M., Ardizzone S., Porro G.B. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 2009, 3:77-97.